Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2015-06-11 | Angus C. Russell, 59, joined our Board of Directors during December 2014. Mr. Russell served as the Chief Executive Officer of Shire plc, a biopharmaceutical company, from June 2008 to April 2013. Angus C. Russell received $8,500 in fees and $23,558 in option awards for a total of $32,058. |
| 2016-04-29 | Angus C. Russell, 60, joined our Board of Directors during December 2014. Mr. Russell served as the Chief Executive Officer of Shire plc... DIRECTOR COMPENSATION table shows Angus C. Russell total compensation of $90,177. |
| 2017-05-01 | Angus C. Russell, 61, joined our Board of Directors during December 2014... The members of the Nominating and Corporate Governance Committee are Neal C. Bradsher (Chairman), Stephen C. Farrell, Michael H. Mulroy, and Angus C. Russell... DIRECTOR COMPENSATION table shows Angus C. Russell total compensation of $84,073. |
| 2018-03-29 | Angus C. Russell, 62, joined our Board of Directors during December 2014. ... The members of the Audit Committee are Deborah Andrews (Chairwoman), Angus C. Russell, and David Schlachet. ... The members of the Nominating and Corporate Governance Committee are Neal C. Bradsher (Chairman), Stephen C. Farrell, and Angus C. Russell. ... DIRECTOR COMPENSATION table shows Angus C. Russell total compensation of $92,801. |
| 2019-06-14 | Angus C. Russell. Mr. Russell served as the Chief Executive Officer of Shire plc, a biopharmaceutical company, from June 2008 to April 2013. ... Mr. Russell brings to our Board numerous years of experience as a Chief Executive Officer of an international publicly traded specialty biopharmaceutical company and his substantial experience as an officer and director in the specialty pharmaceutical industry. ... Committees: Audit ... 2018 Director Compensation ... Angus C. Russell $55,625 Fees Earned or Paid in Cash, $33,045 Option Award, Total $88,670. |
| 2020-08-07 | Angus C. Russell served as the Chief Executive Officer of Shire plc ... The members of our Audit Committee are Deborah Andrews (Chair), Don M. Bailey, and Angus C. Russell. ... Angus C. Russell $50,000 Fees Earned or Paid in Cash, $23,261 Option Award, $73,261 Total. |
| 2021-08-03 | Angus C. Russell. Mr. Russell served as the Chief Executive Officer of Shire plc (SHPG), a biopharmaceutical company, from June 2008 to April 2013. ... Mr. Russell brings to our Board numerous years of experience as a Chief Executive Officer of an international publicly traded specialty biopharmaceutical company and his substantial experience in information systems and security and as an officer and director in the specialty pharmaceutical industry. |
| 2022-04-29 | Angus C. Russell. Mr. Russell served as the Chief Executive Officer of Shire plc (SHPG), a biopharmaceutical company, from June 2008 to April 2013. ... Mr. Russell brings to our Board numerous years of experience as a Chief Executive Officer of an international publicly traded specialty biopharmaceutical company and his substantial experience in information systems and security and as an officer and director in the specialty pharmaceutical industry. ... The following table summarizes certain information concerning the compensation during our fiscal year ended December 31, 2021 to each person who served as a non-employee director during the year and who was not our employee on the date the compensation was earned. ... Angus C. Russell $57,500 Fees Earned or Paid in Cash, $89,555 Option Award, $147,055 Total. |
| 2023-07-27 | Angus C. Russell. Mr. Russell served as the Chief Executive Officer of Shire plc (SHPG), a biopharmaceutical company, from June 2008 to April 2013. ... Mr. Russell brings to our Board numerous years of experience as a Chief Executive Officer of an international publicly traded specialty biopharmaceutical company and his substantial experience in information systems and security and as an officer and director in the specialty pharmaceutical industry. ... The table below shows the average annual cash fees for 2022 and the current cash fees, which became effective as of April 1, 2023. ... The following table summarizes certain information concerning the compensation during our fiscal year ended December 31, 2022 to each person who served as a non-employee director during the year and who was not our employee on the date the compensation was earned. ... Angus C. Russell $62,500 Fees Earned or Paid in Cash, $78,500 Option Award, $141,000 Total. |
| 2024-04-29 | Angus C. Russell. Mr. Russell served as the Chief Executive Officer of Shire plc ... Our Board has determined that Ms. Andrews, Dr. Amin, Mr. Bailey, Mr. Bradsher, Dr. Jayasuriya, Mr. Mulroy, and Mr. Russell qualify as “independent” directors ... The table below sets forth the composition of the committees of our Board as of April 25, 2024: ... Angus C. Russell: Audit Committee Member, Compensation Committee Member ... 2023 Non-Employee Director Compensation Table: Angus C. Russell total $138,000. |
| 2024-12-09 | The Audit Committee of our Board, which is comprised solely of independent directors Ms. Andrews, Messrs. Bailey and Mulroy, and Angus C. Russell. |
| Filing Date | Source Excerpt |
|---|---|
| 2015-04-30 | Angus C. Russell has served as a director of our company since March 2015. ... The Audit Committee currently consists of Messrs. LaPenta, Jr., Collins, Russell, and Segal, each an independent director of our company under the NYSE MKT rules as well as under rules adopted by the SEC pursuant to the Sarbanes-Oxley Act of 2002. Mr. LaPenta, Jr. serves as the Chairman of the Audit Committee. ... The members of the Nominating and Corporate Governance Committee are Messrs. Thompson, Carroll, and LaPenta, Jr. Mr. Thompson serves as Chair. |
| 2016-04-28 | Angus C. Russell has served as a director of our company since March 2015. ... We believe Mr. Russell's extensive experience as a pharmaceutical industry executive and his experience as a director of other publicly traded pharmaceutical companies provides the requisite qualifications, skills, perspectives, and experience that make him well qualified to serve on our Board of Directors. |
| 2017-04-25 | Angus C. Russell has served as a director of our company since March 2015. ... Mr. Russell holds an honorary Doctor of Business Administration from Coventry University, U.K. ... The following table and accompanying footnotes detail compensation paid to our directors for services rendered for the year ended December 31, 2016. Angus C. Russell $71,750 fees earned or paid in cash, $89,503 option awards, total $161,253. |
| 2018-04-27 | Angus C. Russell has served as a director of our company since March 2015. ... The Audit Committee currently consists of Messrs. LaPenta, Jr., Segal, Collins, and Russell. ... Angus C. Russell Fees Earned or Paid in Cash: $68,750, Option Awards: $165,115, Total: $233,865. |
| 2019-04-30 | Angus C. Russell has served as a director of our company since March 2015. ... Member of the Audit Committee. ... Director Compensation table shows $76,250 fees earned in cash and $180,039 option awards, total $256,289. |
| 2020-05-04 | Angus C. Russell has served as a director of our company since March 2015. ... Mr. Russell holds an honorary Doctor of Business Administration from Coventry University, U.K. |
| 2021-04-14 | Angus C. Russell has served as a director of our company since March 2015. Mr. Russell previously served as Chief Executive Officer of Shire PLC from June 2008 until April 2013. Mr. Russell served as the Chief Financial Officer of Shire from 1999 to 2008 and also served as Executive Vice President of global finance. Prior to joining Shire, Mr. Russell served at ICI, Zeneca and AstraZeneca PLC for 19 years, most recently in the role of Vice President, Corporate Finance at AstraZeneca. Mr. Russell also serves as a director of Mallinckrodt PLC [OTC: MNKKKQ], having served as the chairman of the board of Mallinckrodt since May 2018, Lineage Cell Therapeutics, Inc. [NYSE: LCTX] and Revance Therapeutics Inc. [NASDAQ: RVNC], where he serves as the chairman of the board. Mr. Russell previously served as a director of Shire PLC [NASDAQ: SHPG], Questcor Pharmaceuticals Inc. [NASDAQ: QCOR] and InterMune Inc. [NASDAQ: ITMN]. |
Data sourced from SEC filings. Last updated: 2025-12-09